bispecific
dorlixizumab
teplizumab
Ab
countercorrelated
antisynthetase
antipolyvalent
oportuzumab monatox
polyantibody
idiospecific
zanolimumab
alacizumab
soravtansine
fontolizumab
-ab
-zumab
polyvalent
ocrelizumab
carlumab
immunoprecipitant
antinucleosome
durvalumab
agonistic monoclonal antibody
cedelizumab
presentation
biciromab
sulesomab
talizumab
zolimomab
brentuximab
mapatumumab
tigatuzumab
agglutinin
antigenomic
ozoralizumab
antisubstance
evolocumab
heteroclitic
samalizumab
immunospecific
-axo-
vobarilizumab
conatumumab
lucatumumab
patritumab
immunoprobe
ipilimumab
hyperimmunized
nofetumomab
-a-